- Home
- CELH vs CORT Comparison
CELH vs CORT Comparison
Compare CELH & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CELH
- CORT
- Stock Information
- Founded
- CELH 2004
- CORT 1998
- Country
- CELH United States
- CORT United States
- Employees
- CELH N/A
- CORT 500
- Industry
- CELH Beverages (Production/Distribution)
- CORT Biotechnology: Pharmaceutical Preparations
- Sector
- CELH Consumer Staples
- CORT Health Care
- Exchange
- CELH Nasdaq
- CORT Nasdaq
- Market Cap
- CELH 7.5B
- CORT 8.1B
- IPO Year
- CELH N/A
- CORT N/A
- Fundamental
- Price
- CELH $37.44
- CORT $75.99
- Analyst Decision
- CELH Buy
- CORT Strong Buy
- Analyst Count
- CELH 17
- CORT 4
- Target Price
- CELH $47.53
- CORT $142.00
- AVG Volume (30 Days)
- CELH 7.9M
- CORT 1.2M
- Earning Date
- CELH 05-06-2025
- CORT 05-05-2025
- Dividend Yield
- CELH N/A
- CORT N/A
- EPS Growth
- CELH N/A
- CORT 8.36
- EPS
- CELH 0.32
- CORT 1.14
- Revenue
- CELH $1,329,198,000.00
- CORT $685,446,000.00
- Revenue This Year
- CELH $60.96
- CORT $35.85
- Revenue Next Year
- CELH $24.98
- CORT $35.22
- P/E Ratio
- CELH $116.61
- CORT $67.89
- Revenue Growth
- CELH N/A
- CORT 30.93
- 52 Week Low
- CELH $21.10
- CORT $28.04
- 52 Week High
- CELH $80.65
- CORT $117.33
- Technical
- Relative Strength Index (RSI)
- CELH 51.20
- CORT 57.13
- Support Level
- CELH $34.10
- CORT $75.12
- Resistance Level
- CELH $38.35
- CORT $78.70
- Average True Range (ATR)
- CELH 1.64
- CORT 2.78
- MACD
- CELH -0.16
- CORT 0.13
- Stochastic Oscillator
- CELH 45.87
- CORT 66.58
About CELH Celsius Holdings Inc.
Celsius Holdings plays in the energy drink subsegment of the global nonalcoholic beverage market, with 96% of revenue concentrated in North America. Celsius' products contain natural ingredients and a metabolism-enhancing formulation, appealing to fitness and active lifestyle enthusiasts. The firm's portfolio includes its namesake Celsius Originals beverages, Celsius Essentials line (containing aminos), and Celsius On-the-Go powder packets. Celsius dedicates its efforts to branding and innovation, while it utilizes third parties for the manufacturing, packaging, and distribution of its products. In 2022, Celsius forged a 20-year distribution agreement with PepsiCo, which holds an 8.5% stake in the business.
About CORT Corcept Therapeutics Incorporated
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.